CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

Background CD19-directed cancer immunotherapies, based on engineered T cells bearing chimeric antigen receptors (CARs, CAR-T cells) or the systemic administration of bispecific T cell-engaging (TCE) antibodies, have shown impressive clinical responses in relapsed/refractory B-cell acute lymphoblasti...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Manel Juan, Pablo Menendez, Alberto Orfao, Alba Martínez-Moreno, Anaïs Jiménez-Reinoso, Laura Díez-Alonso, Luis Álvarez-Vallina, Aida Falgas, Europa Azucena González-Navarro, Clara Bueno, Heleia Roca-Ho, Javier Arroyo-Ródenas, Francisco J. Gil-Etayo, Alba Pérez-Pons, Óscar Aguilar-Sopeña, Miriam Velasco-Sidro, Marina Gómez-Rosel, Beatriz Jiménez-Matías, Guillermo Muñoz-Sánchez, Yedra Pacheco, Clara Bravo-Martín, Ángel Ramírez-Fernández, Belén Blanco, Pedro Roda-Navarro
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2025-04-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/13/4/e009048.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!